Beacon Equity Research Highlights: Oramed Pharmaceuticals Inc. (ORMP.OB), as the Company Moves Forward with an Investigational New Drug Application
Beacon Equity Research Rates Oramed Pharmaceuticals, Inc. as "Speculative Buy". Oramed Pharmaceuticals, Inc.(ORMP.OB), recently reported a new business initiative. The Israeli company focused on the development of oral delivery solutions based on proprietary technology and Encorium Group, Inc. (Nasdaq: ENCO), an international full service contract research organization (CRO) that provides comprehensive clinical and drug development solutions for pharmaceutical, biotechnology and medical device companies have reached an agreement. The agreement is intended to expedite the development of Oramed's lead product for treatment of diabetes mellitus. Encorium Group has extensive worldwide experience in the drug/biologics development process for a multitude of agents and…
